An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries-Reference-Cited by-同舟云学术

An observational time and motion study of denosumab subcutaneous injection and zoledronic acid intravenous infusion in patients with metastatic bone disease: results from three European countries

Published:2017-04-21 Issue:9 Volume:25 Page:2823-2832
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Body Jean-Jacques,Gatta Francesca,De Cock Erwin,Tao Sunning,Kritikou Persefoni,Wimberger Pauline,Mebis Jeroen,Peeters Marc,Pedrazzoli Paolo,Caraceni Augusto,Adamo Vincenzo,Hechmati Guy

Funder

Amgen (Europe) GmbH

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/article/10.1007/s00520-017-3697-5/fulltext.html

Reference29 articles.

1. Coleman RE (2006) Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 12(20 Pt 2):6243s–6249s. doi: 10.1158/1078-0432.CCR-06-0931

2. Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev 27(3):165–176. doi: 10.1053/ctrv.2000.0210

3. Parker C, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369(3):213–223. doi: 10.1056/NEJMoa1213755

4. Blum RH, Novetsky D, Shasha D, Fleishman S (2003) The multidisciplinary approach to bone metastases. Oncology (Williston Park) 17(6):845–857 discussion 862–843, 867

5. Broder MS, Gutierrez B, Cherepanov D, Linhares Y (2015) Burden of skeletal-related events in prostate cancer: unmet need in pain improvement. Support Care Cancer 23(1):237–247. doi: 10.1007/s00520-014-2437-3

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantifying the administration and monitoring time burden of several disease-modifying therapies for relapsing multiple sclerosis in the United Kingdom: A time and motion study;Multiple Sclerosis and Related Disorders;2024-02

2. Inhibition of RANKL Expression in Osteocyte-like Differentiated Tumor Cells in Giant Cell Tumor of Bone After Denosumab Treatment;Journal of Histochemistry & Cytochemistry;2023-03

3. A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting;PharmacoEconomics - Open;2022-08-23

4. Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study;BioDrugs;2022-04-12

5. Image-guided Cryotherapy for Musculoskeletal Tumors;Current Medical Imaging Formerly Current Medical Imaging Reviews);2021-03-16